Guardant Health, Inc. SEC Filing

Guardant Health insiders reported proposed sales and recent transactions under Form 144.

Rhea-AI Filing Summary

Guardant Health insiders reported proposed sales and recent transactions under Form 144. The filing lists restricted stock lapses of 101 shares on 08/17/2025 and 199 shares on 09/17/2025, and a stock option exercise resulting in 1,000 shares on 03/06/2026 (broker payment for cashless exercise). The excerpt also shows a reported sale of 1,250 shares by Manuel Hidalgo Medina on 12/08/2025 for $131,250.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 04:19 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001865525
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Guardant Health, Inc.
SEC File Number	001-38683
Address of Issuer	3100 HANOVER STREET PALO ALTO CALIFORNIA 94304
Phone	855-698-8887
Name of Person for Whose Account the Securities are To Be Sold	Hidalgo Medina Manuel
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	1300	118997.00	131170441	03/06/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/17/2025	Restricted Stock Lapse	Guardant Health, Inc.			101	08/17/2025	Equity Compensation
Common	09/17/2025	Restricted Stock Lapse	Guardant Health, Inc.			199	09/17/2025	Equity Compensation
Common	03/06/2026	Stock Option Exercise	Guardant Health, Inc.			1000	03/06/2026	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Manuel Hidalgo Medina 3100 HANOVER STREET PALO ALTO CA 94304	Guardant Health, Inc.	12/08/2025	1250	131250.00

144: Remarks and Signature

Remarks
Date of Notice	03/06/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Manuel Hidalgo Medina
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)